Ignite Creation Date:
2024-05-05 @ 7:06 PM
Last Modification Date:
2024-10-26 @ 9:43 AM
Study NCT ID:
NCT00603668
Status:
COMPLETED
Last Update Posted:
2021-08-16
First Post:
2008-01-08
Brief Title:
Phase III Study of Different Doses and Dose Schedules of Milatuzumab hLL1 in CLL
Sponsor:
Gilead Sciences
Organization:
Gilead Sciences
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Chronic Lymphocytic Lymphoma |
Keywords:
| Name | View |
|---|---|
| CLL | View |